CPT® Code 90672

The CPT® Code 90672 refers to the quadrivalent live attenuated influenza virus vaccine (LAIV4) specifically designed for intranasal use. Vaccines, unlike immune globulins that offer short-term, passive immunity, provide active and long-lasting immunity. This is achieved by exposing the recipient's immune system to modified forms of specific viruses or bacteria, prompting the immune system to generate its own antibodies against these pathogens. The immune system retains a memory of how to produce these antibodies, enabling a quicker response upon subsequent exposures to the same antigens. The LAIV4 is a live attenuated vaccine, meaning it contains a weakened form of the live influenza virus. This quadrivalent formulation includes two strains of influenza A and two strains of influenza B, ensuring broader protection against circulating influenza viruses. Administered as a nasal spray, LAIV4 effectively stimulates the immune system to produce antibodies against the influenza virus. Notably, LAIV4 is cold-adapted and temperature-sensitive, allowing the virus to replicate only in the cooler environment of the nose and throat, thus preventing it from spreading to the upper respiratory tract where the body temperature is higher. It is important to note that this code specifically reports the vaccine product itself, and the administration of the vaccine via the intranasal route should be reported separately.